Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome

NCT07209462 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07209462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07209462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 22, 2025
Completion date
October 31, 2027
Enrollment
60 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome